AllergyTalk Episode 12: Changing Biologics, Mucus Viscosity, Pemphigus and Food Allergy

image

Price: FREE for members and non-members

Speaker: Gerald Lee, MD
Viewers can earn credit by completing the post test questions

AllergyTalk is a podcast designed to provide easy access to research summaries from AllergyWatch and recommendations from subject matter experts in order to bring physicians up to date in the latest advances in the field of allergy and immunology.

There is no commercial support for this activity.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers
Fellows-in-Training

Learning Objectives

Upon completion of this activity learners should be able to:

  1. Recognize the response to alternative biologics in patients with severe eosinophilic asthma not controlled with omalizumab.
  2. State the physical properties of nasal secretions in patients with post-nasal drainage.
  3. Recognize allergens as a possible trigger for pemphigus vulgaris.
     
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a "commercial interest" as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
05/21/2020
Course expires: 
05/21/2021
Rating: 
0

All identified conflicts of interest have been resolved.

Stanley Fineman, MD
Disclosures: Independent contractor/contracted research: Aimmune, DVB Technologies, BioCryst, Regeneron; Speaker/honorarium: Boehringer-Ingelheim, Takeda/Shire

Merin Kalangara (Kuruvilla), MD
Nothing to disclose

Gerald Lee, MD
Nothing to disclose

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.